GlassScriptPhysician profile
Randi Katz
NPI 1952012189
$5,590.73
in general payments reported to CMS, 2019-2025
17 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $889 · 2024: $2,576 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,590.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,068.34 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $849.73 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $579.80 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $504.01 | 2023-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $436.94 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $363.57 | 2023-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $349.87 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $293.53 | 2023-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $242.60 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $216.53 | 2023-2025 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $209.17 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $165.78 | 2023-2025 | Auvelity |
| Indivior INC. | $123.95 | 2023-2025 | Perseris, Sublocade |
| Corium, LLC | $62.24 | 2023-2025 | Azstarys |
| Tempus Ai, INC | $52.31 | 2024 | Tempus Pixel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $38.16 | 2025 | Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $34.20 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.